About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Agertm1.1Arnd
targeted mutation 1.1, Bernd Arnold
MGI:2451038
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Agertm1.1Arnd/Agertm1.1Arnd B6.129P2-Agertm1.1Arnd MGI:3694553
hm2
Agertm1.1Arnd/Agertm1.1Arnd involves: 129P2/OlaHsd MGI:3696556
hm3
Agertm1.1Arnd/Agertm1.1Arnd involves: 129P2/OlaHsd * C57BL/6 MGI:3694549


Genotype
MGI:3694553
hm1
Allelic
Composition
Agertm1.1Arnd/Agertm1.1Arnd
Genetic
Background
B6.129P2-Agertm1.1Arnd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Agertm1.1Arnd mutation (0 available); any Ager mutation (29 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
skeleton
• mutants have decreased numbers of osteoclasts per bone surface compared to wild-type
• males have increased cortical thickness at 3 months compared to wild-type males
• at 1 and 3 months of age, males have significantly increased bone mineral content (BMC) compared to male wild-type, as seen in femora of males
• at 1 and 3 months of age, males have significantly increased bone mineral density (BMD) compared to male wild-type, as seen in femora of males
• markedly higher trabecular bone volume in the proximal femur at 3 months
• decreased trabecular spacing
• male mutants have increased trabecular thickness
• increased bone mass is observed in males and females starting at 4 weeks of age
• bone resorption is defective in ovariectomized (OVX) mutants; OVX mutants are resistant to bone loss unlike OVX wild-type mice
• biomechanical bone strength and flexibility is increased in 3-month old mice compared to wild-type

limbs/digits/tail
• males have increased cortical thickness at 3 months compared to wild-type males

homeostasis/metabolism
• mutants exhibit significantly lower serum IL-6 levels at 3 months of age, but not 1 month, compared to wild-type

immune system
• mutants have decreased numbers of osteoclasts per bone surface compared to wild-type
• mutants exhibit significantly lower serum IL-6 levels at 3 months of age, but not 1 month, compared to wild-type

hematopoietic system
• mutants have decreased numbers of osteoclasts per bone surface compared to wild-type




Genotype
MGI:3696556
hm2
Allelic
Composition
Agertm1.1Arnd/Agertm1.1Arnd
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Agertm1.1Arnd mutation (0 available); any Ager mutation (29 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• application of carboxymethyllysine-modified proteins (CML-mps) to rectosigmoid colon of mice does not activate NF kappa B in mutants or induce tissue inflammation whereas both are observed in treated wild-type mice

cellular
• mouse embryonic fibroblasts (MEFs) exhibit impaired chemotaxis in response to HMGB1 compared with wild-type cells
• however, chemotaxis in response to PDGF is normal




Genotype
MGI:3694549
hm3
Allelic
Composition
Agertm1.1Arnd/Agertm1.1Arnd
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Agertm1.1Arnd mutation (0 available); any Ager mutation (29 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• mice show markedly decreased neointimal expansion after femoral artery denudation injury
• after streptozocin treatment, mutants and controls display serum glucose >250 mg/dl; >95% of mice develop diabetes
• after 12 weeks of disease, blood glucose in mutants measures 441 mg/dl, not significantly different from 473 mg/dl in diabetic controls

renal/urinary system
• after 12 weeks of diabetes in mutants, glomerular basement membrane thickness is increased ~3% compared to non-diabetic mutant controls while diabetic wild-type controls show ~14% increased thickness compared to non-diabetic wild-type controls
• after 12 weeks, diabetic mutants display a ~5% increase in glomerular area compared to non-diabetic mutant controls, while diabetic wild-type controls exhibit an increase of ~18% in glomerular area
• after 12 weeks, diabetic mutants display a 6% decrease in mesangial area compared to non-diabetic mutant controls, while diabetic wild-type controls exhibit an increases of ~61%
• diabetic mutant mice show no increase in kidney weight/body weight ratio after 12 weeks of disease whereas diabetic wild-type controls show a 1.6 fold increase in this parameter

cardiovascular system
• VSM cell migration induced by calgranulin b is markedly decreased
• VSM cell proliferation induced by calgranulin b is blunted
• mice show markedly decreased neointimal expansion after femoral artery denudation injury

muscle
• VSM cell migration induced by calgranulin b is markedly decreased
• VSM cell proliferation induced by calgranulin b is blunted

behavior/neurological
• homozygous mice are partially protected from the increased nociceptive threshold caused by diabetes

cellular
• VSM cell proliferation induced by calgranulin b is blunted





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/12/2024
MGI 6.24
The Jackson Laboratory